Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings

Abstract

SummaryAims – To assess using two well-know scales (DAI-30 and SWN) the drug attitude and subjective well-being of patients treated with haloperidol or second-generation antipsychotics (SGA) in four different Italian communities. Methods – The sample included 145 patients taking five different antipsychotics (APs) in mono-therapy: haloperidol, clozapine, olanzapine, risperidone, quetiapine. A stepwise multiple regression analysis (SMRA) was used to analyse the contribution of different AP treatments and of other predictors to SWN and DAI-30 scores. Results – Univariate analyses showed no differences in DAI-30 and SWN scores across treatments. The SMRA showed that SWN scores were negatively correlated with the severity of the psychoses (BPRS scores), while the DAI-30 scores were negatively correlated with the severity of the psychoses and positively correlated both with the length of drug treatment and with the use of olanzapine. Conclusions – Our study does not confirm a better drug attitude in patients treated with SGA with respect to haloperidol. The only partial exception is the better performance of olanzapine over haloperidol on DAI-30, which could be due to the lower use of anticholinergic drugs during olanzapine treatment. The differences between the SWN and DAI-30 may give good reason for the use of both instruments during AP treatments.Declaration of Interest: No grants have been received for this study. In the last two years: Matteo Balestrieri has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Boehringer-Ingelheim, Innova-Pharma, Pfizer, Bristol, Abbott, Lundbeck; Guido Di Sciascio has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Sanofi-Aventis, Wyeth, Boehringer- Ingelheim; Elisa Maso has received grants from Pfizer; Cesario Bellantuono has received grants from Eli Lilly, BMS, Boehringer- Ingelheim, Innova-Pharma, Italfarmaco; The other authors have not received any grants in the last two years.

<p>Attitude Towards Drug Therapy in a Community Mental Health Center Evaluated by the Drug Attitude Inventory</p>

“…It suggests an attitude of trust in drug prescription and, indirectly, in therapeutic relationship with therapists of CMHC. This result is consistent with the literature, which reports higher scores in stabilized outpatient and in long-term care patients, characteristics presented by our participants 51,63 and lower scores in hospitalized and/or acute illness patients. 14,65 We did not find any statistically significant difference in the DAI-30 score between patients suffering from schizophrenic spectrum disorders and those suffering from all other diagnoses.…”

“…Townsend et al 50 used DAI-30 in a sample of 122 adolescent patients diagnosed with heterogeneous psychiatric disorders, where the questionnaire was shown to be a valid tool even changing the dichotomous answers True or False to ones ranged between 1 and 5 in a Likert scale. Balestrieri et al 51 analyzed the attitude towards therapy using the DAI-30 in a homogeneous for pathology sample of 145 patients treated in monotherapy with five different antipsychotics. Similarly, a cross-sectional analysis 52 using the reduced version DAI-10 in 291 patients with schizophrenia highlighted that only some variables, such as family support, insight of illness, therapeutic alliance and number of psychiatric hospitalizations, significantly influenced drug attitude.…”

Attitudes of patients with schizophrenia spectrum or bipolar disorders towards medication self‐management during hospitalisation

“…They agreed that their future health status depends on their medication, and they were concerned about the long‐term effects of their medicines. These results are partially in line with the literature, which reports that outpatients and long‐term care in patients had more positive attitudes about medication than did patients with acute illness (Balestrieri et al., 2009; Medina et al., 2012; Rej et al., 2016). In contrast to the literature, however, we did not find any statistically significant correlations between medication attitude scores and any of the socio‐demographic and clinical variables.…”

Subjective Well-Being in Schizophrenia as Measured with the Subjective Well-Being Under Neuroleptic Treatment Scale: A Review

“…Improvement of subjective well-being was also found in observational studies, without significant differences in typical versus atypical treatment groups [10,39–42]. In studies with a cross-sectional design, subjective well-being in patients treated with atypical or typical antipsychotics was not different [30,43–47].…”